The number of clinical trials testing the efficacy of immune checkpoint inhibitors (ICIs) targeting programmed cell death 1 (PD-1), programmed cell death 1 ligand 1 (PD-L1) and cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4) has increased exponentially. Since the first ICI study was initiated in 2006 to evaluate the PD-1 monoclonal antibody nivolumab, more than 2000 ICI trials actively recruited more than 380 000 volunteers between 2006 and 2018.
1 While early trials commonly tested an anti–PD-1 or anti–PD-L1 agent as monotherapy or doublet therapies, there is an increasing number of trials investigating ICI in combination with chemotherapy or molecularly targeted therapies, such as tyrosine kinase inhibitors, PARP inhibitors, or angiogenesis inhibitors. There is optimism that ICIs will improve overall survival (OS) in a wide range of cancers; hence, there is a high level of interest in ICI trials.